Active Ingredient History
Roflumilast is a specific phosphodiesterase type (4PDE4) inhibitor indicated for use as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alzheimer Disease (Phase 1)
Asthma (Phase 3)
Bronchiectasis (Phase 3)
Bronchitis, Chronic (Phase 4)
Cerebrovascular Disorders (Phase 2)
Cognitive Dysfunction (Phase 2)
Cystic Fibrosis (Phase 2)
Dementia (Phase 2)
Depressive Disorder, Major (Phase 1/Phase 2)
Dermatitis (Phase 2)
Dermatitis, Atopic (Phase 2)
Dermatitis, Seborrheic (Phase 3)
Diabetes Mellitus, Type 2 (Phase 2)
Diabetic Nephropathies (Phase 3)
Drug Interactions (Phase 2)
Emphysema (Phase 4)
Functional Status (Phase 2)
Healthy Volunteers (Phase 1)
Leukemia, B-Cell (Phase 1)
Lung Diseases (Phase 4)
Lymphoma, B-Cell (Phase 1)
Memory (Phase 2)
Memory Disorders (Phase 1)
Metabolic Syndrome (Phase 2)
Neuronal Plasticity (Phase 1)
Non-alcoholic Fatty Liver Disease (Phase 2)
Obesity (Phase 4)
Polycystic Ovary Syndrome (Phase 4)
Prediabetic State (Phase 3)
Psoriasis (Phase 3)
Respiratory Distress Syndrome (Phase 2)
Sarcoidosis (Phase 4)
Schizophrenia (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
